These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Routine and pulse vaccination for Lassa virus could reduce high levels of endemic disease: A mathematical modelling study. Davies J; Lokuge K; Glass K Vaccine; 2019 Jun; 37(26):3451-3456. PubMed ID: 31088745 [TBL] [Abstract][Full Text] [Related]
45. Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. Branco LM; Boisen ML; Andersen KG; Grove JN; Moses LM; Muncy IJ; Henderson LA; Schieffellin JS; Robinson JE; Bangura JJ; Grant DS; Raabe VN; Fonnie M; Zaitsev EM; Sabeti PC; Garry RF Virol J; 2011 Aug; 8():404. PubMed ID: 21843352 [TBL] [Abstract][Full Text] [Related]
46. Lamp1 Increases the Efficiency of Lassa Virus Infection by Promoting Fusion in Less Acidic Endosomal Compartments. Hulseberg CE; Fénéant L; Szymańska KM; White JM mBio; 2018 Jan; 9(1):. PubMed ID: 29295909 [TBL] [Abstract][Full Text] [Related]
47. Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Boisen ML; Hartnett JN; Shaffer JG; Goba A; Momoh M; Sandi JD; Fullah M; Nelson DKS; Bush DJ; Rowland MM; Heinrich ML; Koval AP; Cross RW; Barnes KG; Lachenauer AE; Lin AE; Nekoui M; Kotliar D; Winnicki SM; Siddle KJ; Gbakie M; Fonnie M; Koroma VJ; Kanneh L; Kulakosky PC; Hastie KM; Wilson RB; Andersen KG; Folarin OO; Happi CT; Sabeti PC; Geisbert TW; Saphire EO; Khan SH; Grant DS; Schieffelin JS; Branco LM; Garry RF Sci Rep; 2018 Apr; 8(1):5939. PubMed ID: 29651117 [TBL] [Abstract][Full Text] [Related]
48. Population structure of Lassa Mammarenavirus in West Africa. Forni D; Sironi M Viruses; 2020 Apr; 12(4):. PubMed ID: 32294960 [TBL] [Abstract][Full Text] [Related]
49. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library. Wang P; Liu Y; Zhang G; Wang S; Guo J; Cao J; Jia X; Zhang L; Xiao G; Wang W J Virol; 2018 Aug; 92(16):. PubMed ID: 29899092 [No Abstract] [Full Text] [Related]
50. Mapping the zoonotic niche of Lassa fever in Africa. Mylne AQ; Pigott DM; Longbottom J; Shearer F; Duda KA; Messina JP; Weiss DJ; Moyes CL; Golding N; Hay SI Trans R Soc Trop Med Hyg; 2015 Aug; 109(8):483-92. PubMed ID: 26085474 [TBL] [Abstract][Full Text] [Related]
51. Non-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa Virus. Schaeffer J; Reynard S; Carnec X; Pietrosemoli N; Dillies MA; Baize S Viruses; 2019 Mar; 11(3):. PubMed ID: 30901952 [TBL] [Abstract][Full Text] [Related]
52. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Robinson JE; Hastie KM; Cross RW; Yenni RE; Elliott DH; Rouelle JA; Kannadka CB; Smira AA; Garry CE; Bradley BT; Yu H; Shaffer JG; Boisen ML; Hartnett JN; Zandonatti MA; Rowland MM; Heinrich ML; Martínez-Sobrido L; Cheng B; de la Torre JC; Andersen KG; Goba A; Momoh M; Fullah M; Gbakie M; Kanneh L; Koroma VJ; Fonnie R; Jalloh SC; Kargbo B; Vandi MA; Gbetuwa M; Ikponmwosa O; Asogun DA; Okokhere PO; Follarin OA; Schieffelin JS; Pitts KR; Geisbert JB; Kulakoski PC; Wilson RB; Happi CT; Sabeti PC; Gevao SM; Khan SH; Grant DS; Geisbert TW; Saphire EO; Branco LM; Garry RF Nat Commun; 2016 May; 7():11544. PubMed ID: 27161536 [TBL] [Abstract][Full Text] [Related]
53. Delayed inflammatory and cell death responses are associated with reduced pathogenicity in Lujo virus-infected cynomolgus macaques. Rasmussen AL; Tchitchek N; Safronetz D; Carter VS; Williams CM; Haddock E; Korth MJ; Feldmann H; Katze MG J Virol; 2015 Mar; 89(5):2543-52. PubMed ID: 25520505 [TBL] [Abstract][Full Text] [Related]
54. In-silico identification of the vaccine candidate epitopes against the Lassa virus hemorrhagic fever. Baral P; Pavadai E; Gerstman BS; Chapagain PP Sci Rep; 2020 May; 10(1):7667. PubMed ID: 32376973 [TBL] [Abstract][Full Text] [Related]
55. Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever. Saijo M; Georges-Courbot MC; Marianneau P; Romanowski V; Fukushi S; Mizutani T; Georges AJ; Kurata T; Kurane I; Morikawa S Clin Vaccine Immunol; 2007 Sep; 14(9):1182-9. PubMed ID: 17634509 [TBL] [Abstract][Full Text] [Related]
56. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. Fischer RJ; Purushotham JN; van Doremalen N; Sebastian S; Meade-White K; Cordova K; Letko M; Jeremiah Matson M; Feldmann F; Haddock E; LaCasse R; Saturday G; Lambe T; Gilbert SC; Munster VJ NPJ Vaccines; 2021 Mar; 6(1):32. PubMed ID: 33654106 [TBL] [Abstract][Full Text] [Related]
58. Infection of Human Endothelial Cells with Lassa Virus Induces Early but Transient Activation and Low Type I IFN Response Compared to the Closely-Related Nonpathogenic Mopeia Virus. Merabet O; Pietrosemoli N; Perthame E; Armengaud J; Gaillard JC; Borges-Cardoso V; Daniau M; Legras-Lachuer C; Carnec X; Baize S Viruses; 2022 Mar; 14(3):. PubMed ID: 35337059 [TBL] [Abstract][Full Text] [Related]